Drugs / bacillus Calmette-Guerin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03345134 Background | Nov 2017 → Jan 2021 overdue | renal pelvis/ureter urothelial carcinoma | Shaheen Alanee | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bacillus Calmette-Guerin | “in combination with bacillus Calmette-Guerin (BCG) in high-risk non-muscle invasive UUTUC patients” PMID 31796469 ↗ Dec 2019 |
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03345134 ↗ |
| Route | Other | “in conjunction with intrapelvic BCG” NCT03345134 ↗ |